While many mechanistic details remain to be addressed, our current studies raise the possibility of targeting this traditionally-associated neuroendocrine signaling pathway, as well as RANKL protein, in a therapeutic manner for the treatment of osteosarcoma in dogs and potentially humans as well. Here, TNFSF11 is linked to osteosarcoma.